Literature DB >> 11402649

Absorption of inorganic, trivalent and hexavalent chromium following oral and intrajejunal doses in rats.

H Fébel1, B Szegedi, S Huszár.   

Abstract

The intestinal absorption of trivalent and hexavalent chromium (Cr) given orally (experiment I) or infused in the intestine (experiment II) was investigated in rats. The nonabsorbable form of chromium (51Cr2O3) and water-soluble and more absorbable Na2(51)CrO4 (the hexavalent form of Cr) were compared. Total retention of chromium given orally ranged around 15 percent of the dose, regardless of the chromium compounds applied. The absorption rate of chromic oxide, which is considered a nonabsorbable compound, was 14.4 as a percentage of chromium intake. This result indicates that some loss of chromium has to be taken into account in metabolic trials made by the indicator method. In isolated rat intestine, from the injected Cr 2.5% of chromic oxide and 43.2% of sodium chromate were absorbed during an hour (experiment II). The absorbed chromium was transferred to the liver where the liver tissue retained 10.9% of chromic oxide and 51.1% of sodium chromate. Radioactivity of v. cava caudalis following intestinal injection of Na2CrO4 was thirtyfold greater than after Cr2O3 dosing. This phenomenon can be explained by the lower blood clearance of chromate. Different absorption rate of chromate depending on the route of administration could be due to the fact that the hexavalent form given orally was reduced to Cr3+ in the acidic environment of the stomach. When Na2CrO4 was infused directly in the intestine of rats, such reduction could not occur. This means that the acidic gastric juice might play a role in inhibiting the intestinal absorption of Na2CrO4 when this compound is given orally.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11402649     DOI: 10.1556/004.49.2001.2.10

Source DB:  PubMed          Journal:  Acta Vet Hung        ISSN: 0236-6290            Impact factor:   0.955


  6 in total

1.  Evaluation of hematological, biochemical parameters and thiol enzyme activity in chrome plating workers.

Authors:  Larissa Machado Lacerda; Solange Cristina Garcia; Luciano Basso da Silva; Mariana de Ávila Dornelles; Anelise Teresinha Presotto; Eloir Dutra Lourenço; Itiane Diehl de Franceschi; Elissa Fernandes; Clovis Milton Duval Wannmacher; Natália Brucker; Elisa Sauer; Adriana Gioda; Aline Belem Machado; Evandro Oliveira; Thereza Luciano Trombini; Luciane Rosa Feksa
Journal:  Environ Sci Pollut Res Int       Date:  2018-11-20       Impact factor: 4.223

2.  Exposure to hexavalent chromium resulted in significantly higher tissue chromium burden compared with trivalent chromium following similar oral doses to male F344/N rats and female B6C3F1 mice.

Authors:  Bradley J Collins; Matthew D Stout; Keith E Levine; Grace E Kissling; Ronald L Melnick; Timothy R Fennell; Ramsey Walden; Kamal Abdo; John B Pritchard; Reshan A Fernando; Leo T Burka; Michelle J Hooth
Journal:  Toxicol Sci       Date:  2010-09-15       Impact factor: 4.849

Review 3.  Assessment of the mode of action underlying development of rodent small intestinal tumors following oral exposure to hexavalent chromium and relevance to humans.

Authors:  Chad M Thompson; Deborah M Proctor; Mina Suh; Laurie C Haws; Christopher R Kirman; Mark A Harris
Journal:  Crit Rev Toxicol       Date:  2013-03       Impact factor: 5.635

Review 4.  Application of the U.S. EPA mode of action Framework for purposes of guiding future research: a case study involving the oral carcinogenicity of hexavalent chromium.

Authors:  Chad M Thompson; Laurie C Haws; Mark A Harris; Nicole M Gatto; Deborah M Proctor
Journal:  Toxicol Sci       Date:  2010-10-14       Impact factor: 4.849

5.  Hexavalent chromium is carcinogenic to F344/N rats and B6C3F1 mice after chronic oral exposure.

Authors:  Matthew D Stout; Ronald A Herbert; Grace E Kissling; Bradley J Collins; Gregory S Travlos; Kristine L Witt; Ronald L Melnick; Kamal M Abdo; David E Malarkey; Michelle J Hooth
Journal:  Environ Health Perspect       Date:  2008-12-31       Impact factor: 9.031

6.  A chronic oral reference dose for hexavalent chromium-induced intestinal cancer.

Authors:  Chad M Thompson; Christopher R Kirman; Deborah M Proctor; Laurie C Haws; Mina Suh; Sean M Hays; J Gregory Hixon; Mark A Harris
Journal:  J Appl Toxicol       Date:  2013-08-14       Impact factor: 3.446

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.